Intellectual property

Our growing intellectual property portfolio includes issued patents and pending patent applications in the United States and other markets, covering our approved medicines, product candidates, and related innovations.
Approved products
U.S. patent number(s)
Auvelity®
(dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets 45mg/105mg
8,569,328; 9,168,234; 9,198,905; 9,205,083; 9,238,032; 9,278,095; 9,314,462; 9,370,513; 9,375,429; 9,408,815; 9,421,176; 9,457,023; 9,457,025; 9,474,731; 9,486,450; 9,700,528; 9,700,553; 9,707,191; 9,763,932; 9,861,595; 9,867,819; 9,968,568; 10,058,518; 10,064,857; 10,080,727; 10,092,560; 10,092,561; 10,105,327; 10,105,361; 10,251,879; 10,463,634; 10,512,643; 10,548,857; 10,596,167; 10,772,850; 10,780,064; 10,780,066; 10,786,469; 10,786,496; 10,799,497; 10,806,710; 10,864,209; 10,874,663; 10,874,664; 10,874,665; 10,881,624; 10,881,657; 10,894,046; 10,894,047; 10,898,453; 10,925,842; 10,933,034; 10,940,124; 10,945,973; 10,966,941; 10,966,942; 10,966,974; 11,020,389; 11,058,648; 11,090,300; 11,096,937; 11,123,343; 11,129,826; 11,141,388; 11,141,416; 11,147,808; 11,185,515; 11,191,739; 11,197,839; 11,207,281; 11,213,521; 11,229,640; 11,234,946; 11,253,491; 11,253,492; 11,273,133; 11,273,134; 11,285,118; 11,285,146; 11,291,638; 11,291,665; 11,298,351; 11,298,352; 11,311,534; 11,344,544; 11,357,744; 11,364,233; 11,382,874; 11,419,867; 11,426,370; 11,426,401; 11,433,067; 11,439,636; 11,478,468; 11,497,721; 11,510,918; 11,517,542; 11,517,543; 11,524,007; 11,524,008; 11,534,414; 11,541,021; 11,541,048; 11,596,627; 11,617,728; 11,617,747; 11,717,518; 11,730,706; 11,752,144; 11,779,579; 11,839,612; 11,844,797; 11,883,373; 11,896,563; 11,925,636; 11,969,421; 11,986,444; 12,036,191; 12,042,473; 12,109,178; 12,146,889; and 12,156,914
Sunosi®
(solriamfetol) 75, 150mg tablets
8,440,715; 8,877,806; 9,604,917; 10,351,517; 10,195,151; 10,512,609; 10,912,754; 10,940,133; 10,959,976; 11,160,779; 11,439,597; 11,560,354; 11,648,232; 11,753,368; 11,771,666; 11,771,667; 11,779,554; 11,793,776; 11,839,598; 11,839,599; 11,850,226; 11,850,227; 11,850,228; 11,857,528; 11,865,098; 11,872,203; 11,872,204; 11,969,404; 11,986,454; 11,986,455; 11,998,639; 12,005,036; 12,036,194; 12,064,411; 12,090,126; 12,102,609; 12,194,016; and 12,209,059
Symbravo®
(meloxicam and rizatriptan) 20mg/10mg tablets
9,821,075; 10,029,010; 10,058,614; 10,137,131; 10,195,278; 10,265,324; 10,363,312; 10,369,224; 10,369,225; 10,426,839; 10,463,736; 10,471,014; 10,471,069; 10,512,692; 10,512,693; 10,517,950; 10,532,101; 10,537,642; 10,561,664; 10,583,144; 10,653,777; 10,688,102; 10,688,185; 10,695,429; 10,695,430; 10,702,535; 10,702,602; 10,722,583; 10,729,696; 10,729,697; 10,729,773; 10,758,617; 10,758,618; 10,780,165; 10,780,166; 10,799,588; 10,821,181; 10,821,182; 10,894,053; 10,905,693; 10,918,722; 10,933,136; 10,933,137; 10,940,153; 10,987,358; 11,013,805; 11,013,806; 11,020,483; 11,045,549; 11,135,295; 11,207,328; 11,219,626; 11,285,213; 11,331,323; 11,369,684; 11,426,414; 11,471,464; 11,471,465; 11,504,429; 11,510,927; 11,571,428; 11,602,563; 11,607,456; 11,617,755; 11,617,756; 11,617,791; 11,628,173; 11,712,441; 11,738,085; 11,759,522; 11,801,250; 11,806,354; 11,826,370; 11,865,117; and 12,128,052
Product candidates
AXS-05
>140 issued U.S. patents
>92 issued O.U.S. patents
Claims extending to at least 2043
Multiple pending
AXS-12
Orphan Drug Designation
10 issued U.S. patents and 7 issued O.U.S. patents
Claims extending to at least 2039
Multiple pending
AXS-14
1 issued U.S. patent
Claims extending to at least 2045
Multiple pending